Amylyx Q2 2026 Earnings: Wider Loss as Avexitide Readout Nears

Amylyx Pharmaceuticals (Nasdaq: AMLX) reported a Q2 2026 GAAP net loss of $43.4 million, or $0.39 per basic and diluted share, versus a $41.4 million loss, or $0.46 per share, in Q2 2025; the release did not present a revenue figure. Higher legal costs and commercial preparation lifted operating expenses, while cash, cash equivalents and short-term investments ended June at $250.8 million. The principal near-term event is the Phase 3 LUCIDITY readout for avexitide, expected in late August or early September 2026.

Core financial results

Amylyx’s cost profile shifted during the quarter. R&D expense declined because of lower spending on AMX0035 for progressive supranuclear palsy, partially offset by increased avexitide clinical development and related costs.

SG&A expense rose 40.2%, primarily because of higher legal expenses and investment in commercial strategic initiatives. That increase more than offset the R&D reduction, lifting total operating expenses by 6.6% and widening the net loss by 4.8%.

Higher other income provided a partial offset to the operating expense increase. Stock-based compensation included $2.5 million within R&D and $5.8 million within SG&A.

Pipeline and clinical milestones

Avexitide is the most advanced program and the central near-term driver. The last participant completed the final visit in LUCIDITY’s 16-week double-blind period, leaving the topline efficacy and safety results as the next major step.

Other programs remain earlier in development or require additional controlled studies. The following milestones summarize the latest disclosed status.

LUCIDITY randomized participants 3:2 to receive either 90 mg of avexitide once daily or placebo. Its FDA-agreed primary outcome measures the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16.

Profitability, cash and balance sheet

Cash, cash equivalents and short-term investments declined by $29.0 million, or approximately 10.4%, from $279.8 million on March 31 to $250.8 million on June 30. Amylyx expects this capital to fund operations into 2028 under its current operating plans.

The company reported total assets of $264.6 million, total liabilities of $25.4 million and stockholders’ equity of $239.2 million at quarter-end. Quarterly operating cash flow and free cash flow were not provided, so the sequential cash decline should not be treated as an exact measure of operating cash burn.

A narrower per-share loss did not reflect a smaller net loss

Amylyx’s loss per share improved from $0.46 to $0.39 even though its total net loss increased. The difference resulted from the weighted-average share count rising by approximately 24.7%, from 89.1 million to 111.2 million shares.

The larger denominator reduced the reported loss per share. Investors therefore need to distinguish the EPS movement from the underlying operating result, where expenses and the absolute net loss both increased.

Guidance and upcoming milestones

Amylyx’s forward-looking framework centers on cash duration and pipeline execution rather than revenue or EPS targets. The upcoming LUCIDITY result is particularly important because the company is already undertaking NDA-readiness and pre-commercial work for avexitide.

Recent insider transactions

The provided six-month insider data show 768,170 shares purchased across six transactions and 113,197 shares sold across seven transactions, producing net purchases of 654,973 shares. The individual records below are presented objectively and do not establish insiders’ views about the company’s outlook.

The data also list March 5 stock awards for five executives at a reported price and value of $0, but do not provide the corresponding share quantities.

Risks investors need to watch

• LUCIDITY clinical risk: The pivotal trial’s efficacy and safety results remain pending. An unfavorable or inconclusive readout would directly affect the avexitide regulatory and commercialization timeline.
• Spending ahead of potential approval: SG&A rose as Amylyx invested in commercial strategic initiatives before the Phase 3 result and any regulatory approval. These costs could continue without generating a commercial return if development does not proceed as planned.
• Cash runway assumptions: The expectation of funding operations into 2028 is based on current operating plans. Additional trials, regulatory work or commercialization spending could change the company’s capital requirements.
• Limited evidence for earlier programs: AMX0114 remains in dose escalation, while the Week 96 Wolfram syndrome findings came from an open-label, single-arm study with data from nine participants. Larger controlled studies are still needed.

Summary

Amylyx’s Q2 2026 net loss widened as higher legal and commercial-preparation spending outweighed lower R&D expense, although a larger share count reduced the loss reported per share. The company retains $250.8 million in cash and investments with an expected runway into 2028. The next major test is the LUCIDITY topline result, which will determine whether avexitide can advance toward the company’s planned 2027 submission and potential launch timeline.